Discounted Free Cash Flow
Apr
05
2019
Small Cap Biotech Getting Pricey Again
In May 2015, we warned about rich valuations for small cap Biotech stocks and looked at various ways to evaluate those companies, as the majority have no approved drugs on the market, thus no revenue; therefore, valuing these companies using the conventional methodology is problematic.
current issue
featured articles
recent tags
Bank Lending
(1)
Wealth Effect
(9)
Resession
(1)
Dollar
(55)
Inflation
(584)
Time Cycles
(6)
Oil
(48)
Breakeven Rate
(1)
Value
(130)
Treasuries
(79)
Long T-Bonds
(24)
Active vs. Passive
(17)
Yield Curve
(85)
Economy
(282)
Federal Spending
(2)
Stock Market Performance
(1)
Federal Debt/Deficit
(194)
Fed Policy
(173)
Federal Outlays
(1)
Stimulus
(4)